eXoZymes Inc
EXOZ
$9.76 -2.59% Quote
Exchange NASDAQ Sector Healthcare Industry Biotechnology
Q4 2024
Reported
Published: Dec 31, 2024

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for EXOZ

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

N/A

YoY: N/A

EPS

N/A

YoY: N/A

Market Move

-2.59%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Net Income

-3.67M

YoY: -234.3%

EXOZ
Company EXOZ

Swipe to view all report sections

Executive Summary

eXoZymes Inc (EXOZ) reported a fourth quarter of 2024 characterized by substantial operating losses and negative EBITDA, with no disclosed revenue for QQ4 2024. Key operating costs remained elevated, driven by R&D and general and administrative expenses, totaling approximately $3.97 million in operating expenses for the quarter, and contributing to a net loss of roughly $3.67 million. EBITDA stood at approximately -$3.83 million and the quarterly operating income was -$3.97 million. The company did, however, bolster liquidity through a significant equity financing event, generating cash proceeds of about $15.4 million and increasing shares outstanding to roughly 8.13 million on a diluted basis, which supported a cash balance of about $9.72 million at quarter-end.

From a balance sheet perspective, EXOZ maintains ample liquidity, with a current ratio reported at 8.12x and a cash position that broadly covers near-term liabilities. Total liabilities amounted to approximately $2.61 million against equity of about $10.42 million, leaving a negative retained earnings balance of roughly -$11.95 million and suggesting that the current capitalization relies on continued external funding rather than operating profitability.

Looking ahead, the absence of quarterly revenue and a lack of explicit forward guidance heighten execution risk. The companyโ€™s ability to monetize its SimplePath platform and translate pipeline progress into revenue will be the key driver for a sustainable investment thesis. Near-term investors should monitor (i) any licensing partnerships or milestone-based collaborations, (ii) the cadence of R&D progress and potential grant funding, and (iii) subsequent financing needs and dilution risk. While the liquidity runway appears favorably positioned in the near term, long-term value creation will depend on achieving meaningful commercial milestones and/or strategic partnerships that unlock revenue and improve unit economics.

Key Performance Indicators

Operating Income
Decreasing
-3.97M
QoQ: -146.11% | YoY: -302.68%
Net Income
Decreasing
-3.67M
QoQ: -121.69% | YoY: -234.25%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -0.28 +0.0% View
Q4 2024 0.00 0.00 +0.0% View
Q3 2024 0.00 -0.20 +0.0% View
Q2 2024 0.00 0.00 +0.0% View
Q1 2024 0.00 -0.12 +0.0% View